vincristine..... 2.0 mg/sqm IV day 1.
actinomycin..... 2.0 mg/sqm IV day 1.
cytoxan......... 1,200 mg/sqm IV day 1.
FREQUENCY....... Repeat cycle every 28 days.
Kinsella TJ. Triche TJ. Dickman PS. Costa J. Tepper JE.
Glaubiger D. Extraskeletal Ewing's sarcoma: results of
combined modality treatment. Journal of Clinical Oncology.
1(8):489-95, 1983 Aug.
Eleven patients with extraskeletal Ewing's sarcoma (EES) were
treated with combined modality therapy at the National Cancer
Institute. The diagnosis of EES was reserved for lesions that
were identical to Ewing's sarcoma of bone by light and
electron microscopy. Diagnostic work-up to rule out a skeletal
primary included bone scan, localized views of adjacent bone,
and bone tomography. Seven patients presented with an
extremity primary and four patients had a truncal primary. No
patients had evidence of metastases at presentation. Patients
were treated with combined modality therapy consisting of
high-dose local irradiation and vincristine, actinomycin D,
and cyclophosphamide chemotherapy following a biopsy or local
excision. No attempt was made to excise widely the primary
tumor mass. Gross tumors generally responded rapidly to the
combined modality treatment. Of 11 patients, seven (64%)
remain disease free, with a follow-up of three to seven years
from completion of therapy. Long-term local control was
established in nine of 11 patients (82%). Autopsy findings on
two patients with local failure showed no tumor involvement of
adjacent bone. Attempts at gross resections by radical
surgical procedures do not routinely appear to be necessary in
light of the high local control rates with high-dose